Altre lingue Lotus Pharmaceutical Co., Ltd.

Azioni

1795

TW0001795003

Prezzo di chiusura Taiwan S.E. Altri mercati azionari 00:00:00 17/05/2024			Variaz. 5gg	Var. 1 gen.
301 ^TWD	+4,88%		+4,70%	+10,66%

11/05	Lotus Pharmaceutical Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
26/03	Lotus Pharmaceutical Co., Ltd. annuncia il cambio del Rappresentante del Direttore Istituzionale della Società	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	26/03
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	31/01
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/01
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth	11/01
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth	12/10/23
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.	25/09/23
Lotus Pharmaceutical Co., Ltd. Announces Director Changes	04/09/23
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15/08/23
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia	10/08/23
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA	02/08/23
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	31/07/23
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	12/07/23
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	11/07/23
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson	10/07/23
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members	10/07/23
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023	16/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Lotus Pharmaceutical Co., Ltd.

Azioni

1795

TW0001795003

Altre lingue

Filtri